<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00587691</url>
  </required_header>
  <id_info>
    <org_study_id>2000-03</org_study_id>
    <nct_id>NCT00587691</nct_id>
  </id_info>
  <brief_title>Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis</brief_title>
  <acronym>DES</acronym>
  <official_title>An Open-Label, Dose-Escalation Study of T Cell Vaccine in Multiple Sclerosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Opexa Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Opexa Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is 1) to study the safety and tolerability of escalating doses of
      myelin peptide reactive T cells in MS patients and 2) to study the clinical effectiveness of
      T Cell Vaccine ion the clinical course of MS.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principle of TCV is similar to that of traditional microbial vaccination where attenuated
      infectious agents are used to stimulate protective immune responses. Because pathogentic
      autoreactive T cells are viewed as pathogens in T cell-mediated autoimmune diseases, they can
      be used, as a vaccine to prevent and treat the diseases in which they are able to induce.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2002</start_date>
  <completion_date type="Actual">December 2008</completion_date>
  <primary_completion_date type="Actual">June 2007</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Evaluation of safety and tolerability</measure>
    <time_frame>Yearly Intervals</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess changes in EDSS Scores</measure>
    <time_frame>Yearly Intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in the myelin-reactive profile in the blood</measure>
    <time_frame>Yearly Intervals</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess changes in the frequency of MS relapses</measure>
    <time_frame>Yearly Intervals</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Multiple Sclerosis, Relapsing-Remitting</condition>
  <condition>Multiple Sclerosis, Secondary Progressive</condition>
  <arm_group>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6-9 million MRTC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>30-45 million MRTC</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>60-90 million MRTC</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tovaxin Autologous T Cell Vaccine</intervention_name>
    <description>Primary Series (x1): 4 subcutaneous injections (wks 0, 4, 12 and 20 with 52 week evaluable period.
Retreatment Series (x3): 3 subcutaneous injections (wks 0, 4, and 8) with 26-week evaluable periods.
Retreatment Series (x3): 5 subcutaneous injections (wks 0, 8, 26, 24 and 32) with 52-week evaluable periods.</description>
    <arm_group_label>Dose Level 1</arm_group_label>
    <arm_group_label>Dose Level 2</arm_group_label>
    <arm_group_label>Dose Level 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Stable MS disease within 30 days prior to enrollment

          -  EDSS Score between 2 and 8 inclusively

          -  Failed to respond to or cannot tolerate at least 1 or more of the currently approved
             drugs for MS.

        Exclusion Criteria:

          -  Women who are pregnant or breast-feeding or who plan to become pregnant during the
             study

          -  Has taken immunomodulating drugs within 60 days prior to screening

          -  HIV positive
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jaye Thompson, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Opexa Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bellaire Neurology</name>
      <address>
        <city>Bellaire</city>
        <state>Texas</state>
        <zip>77401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Zhang J. T-cell vaccination in multiple sclerosis: immunoregulatory mechanism and prospects for therapy. Crit Rev Immunol. 2001;21(1-3):41-55. Review.</citation>
    <PMID>11642613</PMID>
  </reference>
  <reference>
    <citation>Zhang J. T-cell vaccination for autoimmune diseases: immunologic lessons and clinical experience in multiple sclerosis. Expert Rev Vaccines. 2002 Oct;1(3):285-92. Review.</citation>
    <PMID>12901569</PMID>
  </reference>
  <reference>
    <citation>Zhang JZ, Rivera VM, Tejada-Simon MV, Yang D, Hong J, Li S, Haykal H, Killian J, Zang YC. T cell vaccination in multiple sclerosis: results of a preliminary study. J Neurol. 2002 Feb;249(2):212-8.</citation>
    <PMID>11985389</PMID>
  </reference>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2007</study_first_submitted>
  <study_first_submitted_qc>December 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2008</study_first_posted>
  <last_update_submitted>January 9, 2017</last_update_submitted>
  <last_update_submitted_qc>January 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tovaxin</keyword>
  <keyword>TCV</keyword>
  <keyword>Autologous</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis</mesh_term>
    <mesh_term>Multiple Sclerosis, Relapsing-Remitting</mesh_term>
    <mesh_term>Multiple Sclerosis, Chronic Progressive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

